Fidasimtamab, designated DLTV – 1504, represents the innovative avenue in the battle against multiple myeloma. The drug is a dual-specific antibody designed to simultaneously engage CD3-positive https://bh2950889940.veronicablog.com/62162026/fidasimtamab-a-new-hope-in-relapsed-refractory-myeloma-therapy